What after Osimertinib failure?

Abhishek Pathak, Professor at the Indian Army, shared a post on X:

“What after Osimertinib failure?

Results from MARIPOSA 2.

PFS advantage at best. Did Lazertinib really help?”

Antonio Passaro, Medical Oncologist at the European Institute of Oncology, shared this post, adding:

“Chemo plus ami will be the new standard, approved by FDA/EMA.

No lazertinib required…”

Sources: Abhishek Pathak/X and Antonio Passaro/X